Solidarity Projects for Christmas 2020
Children are our future and, in such a particular year, we decided to invest the Christmas gifts budget in 2 projects with the aim to make a small improvement in thousands of children’s lives.
Our help to AISM and Tettamanti Foundation* which, with their contribution, continuously improve scientific research in the field of multiple sclerosis and leukemia, is a hope message for a better future.
FPZ contributes to AISM’s research on pediatric multiple sclerosis, in order to develop an application for smartphones and tablets necessary for the cognitive rehabilitation.
Research support on pediatric multiple sclerosis
In Italy there are 126,000 multiple sclerosis patients of which only 10 out of 100 receive a diagnosis before the age of 18 and 3-5 before 16 years. Due to the current Covid-19 emergency, many people with multiple sclerosis had repercussions on their living conditions.
Considering all the multiple sclerosis centers, 91% suffered an impact on their facility, 43% had patients and care providers infected with Covid-19, 40% had problems accessing intensive care, 75% had interrupted rehabilitation therapies and 14% lost their jobs.
In such a difficult period, FPZ decided to support one of the projects of AISM, an organization that takes care of people with multiple sclerosis by financing scientific research, guaranteeing social services and promoting people rights.
Thanks to the contribution of our customers and suppliers, we are supporting an important research project on pediatric multiple sclerosis that regards the development of a smartphone and tablet application, designed for the cognitive rehabilitation. It is based on personalized memory exercises for improving the quality of life.
To all these children and their families, we would like to offer a better future by supporting the AISM research and its Foundation.
Tettamanti Foundation project
FPZ contributes to the study on some innovative pharmacological treatments against leukemia in children realized by Tettamanti Foundation (Maria Letizia Verga Center – Monza, Italy), by acquiring a cell incubator.
Innovative pharmacological treatments against leukemia in children
B cell acute lymphoblastic leukemia (B-LLA) is the most common cancer in children. Today, thanks to medical advances made in recent decades, it’s treatable in 80% of cases.
However, some patients (so-called “high risk”) have a complex prognosis, due to resistance to conventional therapies and a high risk of relapse. Tettamanti Foundation’s research focuses mainly on these “frail” patients. One of the foundation’s aims is to identify the genes involved in the pathogenesis of leukemia responsible for the onset and progression of the disease.
Thanks to the contribution of our customers and suppliers, we are supporting this important research through the purchase of a cell incubator HERAcell 150i (Thermo Scientific) essential for cultivating leukemia cells in appropriate physical and environmental conditions.
Through the use of cells grown in the HERAcell 150i incubator it is possible to study the role that some genes (for example the Musashi 2 gene in leukemia with onset in the first year of life) have in the proliferation of leukemia cells in vitro.
Studying these genes represents the key to understanding the biological mechanisms in which they are involved, providing the basis for the identification of new therapeutic targets and the development of alternative therapies specific for these “frail” patients in order to improve their expectation of life.
*Tettamanti Foundation Onlus was established in 1995, thanks to the donation of Rita Minola Fusco, in memory of the parents Matilde Tettamanti and Menotti De Marchi, and to the Maria Letizia Verga Committee. Since 1987, within it, The Matilde Tettamanti Research Center has been operating. It is specialized in the field of research on childhood leukemia and hemopathies and the first example in Italy of a research structure in this area that operates in an integrated way with a treatment facility, the pediatric Clinic of the MBBM Foundation of the San Gerardo Hospital in Monza. Using the most sophisticated molecular techniques, the Center diagnoses and monitors the genetic anomalies present in leukemic children in all Italian treatment centers, assisting about 400 children a year, at the onset of the disease. It includes four research units, each of which coordinates the work of 35 researchers and 15 technicians and biologists.